Compare MasterCard Inc (MA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Viatris Inc — how do they compare? MasterCard Inc trades at $538.35 (market cap $483.71B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: MasterCard Inc is far larger — about 24.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MA | VTRS | |
|---|---|---|
Market Cap | $483.71B | $19.79B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $17.39 |
52-Week Low | $471.55 | $8.74 |
Enterprise Value | $494.45B | $32.00B |
Dividend Yield | 0.64% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $538.30, down 0.97% on the day, with a bullish technical outlook supported by moving averages and strong price targets. The company demonstrates robust fundamentals with revenue growth from $32.79B in 2025 to a projected $33.9B in 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion.
The outlook remains positive given Wall Street's strong buy consensus and a $634.27 price target, though high valuation multiples and competitive disruption from new payment technologies present risks. Earnings growth and market leadership are key catalysts for upside.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
